Publications by authors named "Jonathan P Solecki"
Introduction: The ubiquitin-proteasome system (UPS) is an intracellular organelle responsible for targeted protein degradation, which represents a standard therapeutic target for many different human malignancies. Bortezomib, a reversible inhibitor of chymotrypsin-like proteasome activity, was first approved by the FDA in 2003 to treat multiple myeloma and is now used to treat a number of different cancers, including relapsed mantle cell lymphoma, diffuse large B-cell lymphoma, colorectal cancer, and thyroid carcinoma. Despite the success, bortezomib and other proteasome inhibitors are subject to severe side effects, and ultimately, drug resistance.
View Article and Find Full Text PDFLoss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
Mayra A Gonzalez Idaly M Olivas Alfonso E Bencomo-Alvarez Andres J Rubio Christian Barreto-Vargas Jonathan P Solecki
Clin Transl Med
December 2022
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukaemia (CML) from a deadly condition into a manageable one, but drug-resistant leukaemia stem cells present a significant challenge for achieving a cure.
- A new study highlights the downregulation of the G0/G1 switch gene 2 (G0S2), a key regulator of lipid metabolism, in various instances of TKI resistance, which correlates with poorer survival outcomes for patients.
- The research indicates that the decrease in G0S2 is influenced by transcriptional repression from MYC rather than by genetic changes or BCR::ABL1 activity, suggesting that restoring G0S2 could be crucial for improving treatment responses
Article Synopsis
- Recent research highlights PSMD1 and PSMD3 as potential prognostic biomarkers in both chronic myeloid leukemia and various solid tumors.
- In acute myeloid leukemia (AML), higher levels of PSMD3 expression were linked to poorer overall survival in patients with FLT3 mutations, while knocking down PSMD3 in cell lines improved survival rates in experimental models.
- The study also uncovered additional proteasome subunits that were upregulated in FLT3-mutated AML patients, indicating a need to explore these components as prognostic indicators for AML and other cancers.